UTHR

United Therapeutics Corporation

October 1, 2026 · pre-market open

Rarity

2.64

Peak move

+8.01%

Float cap

$22.8B

United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for people with serious diseases and unmet medical needs. It markets and sells treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. Its products are sold primarily in the United States, with some sales in select international markets.

• analyst_ratingOct 1

  BTIG upgraded United Therapeutics to Buy from Neutral with a $728 price target, citing the '327 patent ruling as a significant impediment to Liquidia's Yutrepia in PH-ILD and IPF optionality with an April 2027 PDUFA date.

  Webmarketscreener.comWebinvesting.comWebbenzinga.com
• Key eventanalyst_ratingOct 1

  BofA Securities lowered its price target on United Therapeutics to $559 from $613, maintaining a Neutral rating, after the company said it would no longer reaffirm its prior Tyvaso sales guidance.

  Webes.investing.com
• buybackOct 1

  United Therapeutics entered the final tranche of an accelerated share repurchase agreement covering the remaining $477.6 million of its $2.0 billion authorization, executed with Citibank.

  Webfr.investing.com
• insider_saleSep 30 · 16:30 ET

  Chairperson & CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics on September 29, 2026 at prices of $472.05-$486.77 for about $4.54 million, exercised 19,000 options at $117.76, and left 324,443 shares held.

  SEC4 0001106578-26-000152
• Key eventlitigation_outcomeSep 30 · 15:41 ET

  The US District Court for the District of Delaware ruled that Liquidia's Yutrepia (treprostinil) inhalation powder infringes claims 1 and 14 of United Therapeutics' '327 patent covering inhaled treprostinil for PH-ILD, while the four other asserted claims were invalidated; the parties have one week to submit a proposed judgment with remedies.

  Webmarketscreener.comWebmarketscreener.comWebmalaysia.news.yahoo.comWebmarketscreener.comWebsec.govWebuk.investing.comWebbenzinga.comWebayondo.comWebmarketscreener.comWebreuters.comWebbenzinga.com
• Key eventregulatory_approvalSep 30 · 13:25 ET

  The FDA accepted United Therapeutics' supplemental new drug application for nebulized Tyvaso in idiopathic pulmonary fibrosis, with a review decision expected around late April 2027, backed by the Phase 3 TETON-1 and TETON-2 trials.

  Webweissratings.comWebunited-therapeutics-ir.cd.invdcloud-is.usWebbusinesswirenews.com
• peer_disclosureSep 30

  Liquidia CEO Roger Jeffs said the company disagrees with the Delaware court's ruling on claims 1 and 14 of United Therapeutics' '327 patent, will pursue all appellate options, and intends to submit a supplement to Yutrepia's New Drug Application asking the FDA to remove the PH-ILD indication from the label.

  Webbenzinga.com
• analyst_ratingSep 30

  Cantor Fitzgerald analyst Olivia Brayer Saunders said United Therapeutics' path to $1,000 'just got easier' after the patent ruling, maintaining an Overweight rating and $700 price target on the shares.

  Webtipranks.com
• insider_saleSep 29 · 16:33 ET

  United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised 19,000 options at $117.76 and sold 9,500 shares on September 28, 2026 at prices from $472.43 to $486.00 for about $4.57 million under a Rule 10b5-1 plan, leaving 324,443 shares held.

  SEC4 0001106578-26-000151Websec.gov